High neutrophil‐to‐lymphocyte ratio predicts poor clinical outcome in patients with castration‐resistant prostate cancer treated with docetaxel chemotherapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1442-2042|22|9|827-833

ISSN： 0919-8172

Source： INTERNATIONAL JOURNAL OF UROLOGY, Vol.22, Iss.9, 2015-09, pp. : 827-833

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial Comment to High neutrophil‐to‐lymphocyte ratio predicts poor clinical outcome in patients with castration‐resistant prostate cancer treated with docetaxel chemotherapy

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 9, 2015-09 ,pp. : 834-834

John Wiley & Sons Inc

Access to resources Recommend Favorite

Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio

By  

CANCER, Vol. 120, Iss. 21, 2014-11 ,pp. : 3346-3352

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 250-256

John Wiley & Sons Inc

Access to resources Recommend Favorite

Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Advanced Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy

By  

Oncology, Vol. 82, Iss. 5, 2012-04 ,pp. : 261-268

Karger

Access to resources Recommend Favorite

Feasibility of Tri-Weekly Docetaxel-Based Chemotherapy for Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer

By  

Urologia Internationalis, Vol. 87, Iss. 3, 2011-08 ,pp. : 263-269

Karger

Access to resources Recommend Favorite